vs
Alkermes plc.（ALKS）与LiveRamp Holdings, Inc.（RAMP）财务数据对比。点击上方公司名可切换其他公司
Alkermes plc.的季度营收约是LiveRamp Holdings, Inc.的1.8倍（$384.5M vs $212.2M），LiveRamp Holdings, Inc.净利率更高（18.8% vs 12.8%，领先6.0%），LiveRamp Holdings, Inc.同比增速更快（8.6% vs -10.6%），过去两年LiveRamp Holdings, Inc.的营收复合增速更高（11.1% vs 4.8%）
Alkermes plc是一家全产业链布局的生物制药企业，专注于精神障碍与神经系统疾病相关药物的研发。公司1987年由迈克尔·沃尔创立，2011年9月与原Élan集团旗下的药物制剂及生产部门Elan Drug Technologies合并，总部位于都柏林，在马萨诸塞州沃尔瑟姆设有研发中心，俄亥俄州威尔明顿建有生产基地。
LiveRamp Holdings, Inc.是一家美国SaaS企业，核心业务为提供数据连接平台，服务涵盖数据导入、线下数据线上迁移等能力，助力企业开展营销相关的数据应用，为品牌及营销从业者的数字化运营提供技术支撑。
ALKS vs RAMP — 直观对比
营收规模更大
ALKS
是对方的1.8倍
$212.2M
营收增速更快
RAMP
高出19.2%
-10.6%
净利率更高
RAMP
高出6.0%
12.8%
两年增速更快
RAMP
近两年复合增速
4.8%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $384.5M | $212.2M |
| 净利润 | $49.3M | $39.9M |
| 毛利率 | 88.0% | 71.9% |
| 营业利润率 | 15.1% | 18.6% |
| 净利率 | 12.8% | 18.8% |
| 营收同比 | -10.6% | 8.6% |
| 净利润同比 | -66.3% | 255.7% |
| 每股收益（稀释后） | $0.29 | $0.62 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALKSRAMP
| Q4 25 | $384.5M | $212.2M | ||
| Q3 25 | $394.2M | $199.8M | ||
| Q2 25 | $390.7M | $194.8M | ||
| Q1 25 | $306.5M | $188.7M | ||
| Q4 24 | $430.0M | $195.4M | ||
| Q3 24 | $378.1M | $185.5M | ||
| Q2 24 | $399.1M | $176.0M | ||
| Q1 24 | $350.4M | $171.9M |
净利润ALKSRAMP
| Q4 25 | $49.3M | $39.9M | ||
| Q3 25 | $82.8M | $27.4M | ||
| Q2 25 | $87.1M | $7.7M | ||
| Q1 25 | $22.5M | $-6.3M | ||
| Q4 24 | $146.5M | $11.2M | ||
| Q3 24 | $92.4M | $1.7M | ||
| Q2 24 | $91.4M | $-7.5M | ||
| Q1 24 | $36.8M | $-5.4M |
毛利率ALKSRAMP
| Q4 25 | 88.0% | 71.9% | ||
| Q3 25 | 86.9% | 70.2% | ||
| Q2 25 | 87.3% | 70.1% | ||
| Q1 25 | 83.9% | 69.3% | ||
| Q4 24 | 85.6% | 71.9% | ||
| Q3 24 | 83.3% | 72.4% | ||
| Q2 24 | 84.6% | 70.6% | ||
| Q1 24 | 83.3% | 72.2% |
营业利润率ALKSRAMP
| Q4 25 | 15.1% | 18.6% | ||
| Q3 25 | 22.6% | 10.7% | ||
| Q2 25 | 23.8% | 3.7% | ||
| Q1 25 | 4.5% | -6.1% | ||
| Q4 24 | 37.8% | 7.5% | ||
| Q3 24 | 27.7% | 4.0% | ||
| Q2 24 | 27.5% | -3.0% | ||
| Q1 24 | 12.4% | -8.3% |
净利率ALKSRAMP
| Q4 25 | 12.8% | 18.8% | ||
| Q3 25 | 21.0% | 13.7% | ||
| Q2 25 | 22.3% | 4.0% | ||
| Q1 25 | 7.3% | -3.3% | ||
| Q4 24 | 34.1% | 5.7% | ||
| Q3 24 | 24.4% | 0.9% | ||
| Q2 24 | 22.9% | -4.3% | ||
| Q1 24 | 10.5% | -3.1% |
每股收益（稀释后）ALKSRAMP
| Q4 25 | $0.29 | $0.62 | ||
| Q3 25 | $0.49 | $0.42 | ||
| Q2 25 | $0.52 | $0.12 | ||
| Q1 25 | $0.13 | $-0.10 | ||
| Q4 24 | $0.88 | $0.17 | ||
| Q3 24 | $0.55 | $0.03 | ||
| Q2 24 | $0.53 | $-0.11 | ||
| Q1 24 | $0.21 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $388.6M | $403.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.8B | $962.3M |
| 总资产 | $2.5B | $1.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALKSRAMP
| Q4 25 | $388.6M | $403.4M | ||
| Q3 25 | $616.4M | $376.9M | ||
| Q2 25 | $521.2M | $371.1M | ||
| Q1 25 | $399.8M | $420.8M | ||
| Q4 24 | $291.1M | $384.3M | ||
| Q3 24 | $396.3M | $348.4M | ||
| Q2 24 | $535.1M | $342.7M | ||
| Q1 24 | $420.8M | $368.9M |
股东权益ALKSRAMP
| Q4 25 | $1.8B | $962.3M | ||
| Q3 25 | $1.7B | $943.8M | ||
| Q2 25 | $1.6B | $947.8M | ||
| Q1 25 | $1.5B | $948.9M | ||
| Q4 24 | $1.5B | $957.7M | ||
| Q3 24 | $1.3B | $932.1M | ||
| Q2 24 | $1.3B | $951.9M | ||
| Q1 24 | $1.3B | $949.1M |
总资产ALKSRAMP
| Q4 25 | $2.5B | $1.3B | ||
| Q3 25 | $2.3B | $1.2B | ||
| Q2 25 | $2.3B | $1.2B | ||
| Q1 25 | $2.1B | $1.3B | ||
| Q4 24 | $2.1B | $1.3B | ||
| Q3 24 | $2.2B | $1.2B | ||
| Q2 24 | $2.2B | $1.2B | ||
| Q1 24 | $2.1B | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $170.1M | — |
| 自由现金流经营现金流 - 资本支出 | $170.0M | — |
| 自由现金流率自由现金流/营收 | 44.2% | — |
| 资本支出强度资本支出/营收 | 0.0% | 0.1% |
| 现金转化率经营现金流/净利润 | 3.45× | — |
| 过去12个月自由现金流最近4个季度 | $480.3M | — |
8季度趋势，按日历期对齐
经营现金流ALKSRAMP
| Q4 25 | $170.1M | — | ||
| Q3 25 | $101.7M | $57.4M | ||
| Q2 25 | $150.2M | $-15.8M | ||
| Q1 25 | $98.8M | — | ||
| Q4 24 | $190.4M | $45.1M | ||
| Q3 24 | $81.6M | $55.6M | ||
| Q2 24 | $146.0M | $-9.3M | ||
| Q1 24 | $21.1M | — |
自由现金流ALKSRAMP
| Q4 25 | $170.0M | — | ||
| Q3 25 | $84.4M | $56.8M | ||
| Q2 25 | $137.2M | $-16.2M | ||
| Q1 25 | $88.7M | — | ||
| Q4 24 | $180.6M | $44.8M | ||
| Q3 24 | $73.3M | $55.4M | ||
| Q2 24 | $138.9M | $-9.6M | ||
| Q1 24 | $12.8M | — |
自由现金流率ALKSRAMP
| Q4 25 | 44.2% | — | ||
| Q3 25 | 21.4% | 28.4% | ||
| Q2 25 | 35.1% | -8.3% | ||
| Q1 25 | 28.9% | — | ||
| Q4 24 | 42.0% | 22.9% | ||
| Q3 24 | 19.4% | 29.8% | ||
| Q2 24 | 34.8% | -5.4% | ||
| Q1 24 | 3.6% | — |
资本支出强度ALKSRAMP
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 4.4% | 0.3% | ||
| Q2 25 | 3.3% | 0.2% | ||
| Q1 25 | 3.3% | 0.2% | ||
| Q4 24 | 2.3% | 0.1% | ||
| Q3 24 | 2.2% | 0.1% | ||
| Q2 24 | 1.8% | 0.1% | ||
| Q1 24 | 2.4% | 1.0% |
现金转化率ALKSRAMP
| Q4 25 | 3.45× | — | ||
| Q3 25 | 1.23× | 2.09× | ||
| Q2 25 | 1.72× | -2.04× | ||
| Q1 25 | 4.40× | — | ||
| Q4 24 | 1.30× | 4.02× | ||
| Q3 24 | 0.88× | 32.10× | ||
| Q2 24 | 1.60× | — | ||
| Q1 24 | 0.57× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALKS
| Vivitrol | $124.1M | 32% |
| Aristada And Aristada Initio | $97.2M | 25% |
| LYBALVI | $94.1M | 24% |
| Royalty | $65.7M | 17% |
| Manufacturing Revenue | $3.3M | 1% |
RAMP
暂无分部数据
